Oric Pharmaceuticals to present rinzimetostat data at AACR2026

Oric Pharmaceuticals to present rinzimetostat data at AACR2026
Oric Pharmaceuticals to present at AACR2026

Oric Pharmaceuticals announced that two preclinical abstracts detailing the potential of rinzimetostat (ORIC-944) for prostate cancer treatment have been accepted for poster presentation at the AACR2026 annual meeting scheduled for April 17-22, 2026.

The abstracts support the positioning of rinzimetostat as a best-in-class therapeutic candidate. The American Association for Cancer Research (AACR) conference is a prominent platform for unveiling new cancer research findings, highlighting Oric Pharmaceuticals' role in advancing prostate cancer therapies.

The company's heightened profile at AACR2026 follows a period of internal focus, underscored by initiatives such as its recent emphasis on team recognition and wellness, as highlighted during Oric Pharmaceuticals' observance of Employee Appreciation Day. Such efforts reflect a comprehensive approach to both scientific innovation and employee engagement as Oric advances its therapeutic pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.